新型降尿酸药非布索坦的临床研究进展(4)
[19] Reza Khosravan，Brian A. Grabowski，Jing-Tao Wu，et al. Pharmacokinetics， pharmacodynamics and safety of febuxostat，a non-purine selective inhibitor of xanthine oxidase， in a dose escalation study in healthy subjects[J].Clin Pharmacokinet，2006，45(8)：821-841.
[20] Michael A. Becker，H. Ralph Schumacher，Jr. Robert L. Wortmann，et al.Febuxostat， a novel nonpurine selective inhibitor of xanthine oxidase a twenty-eight-day， multicenter， phase II， randomized， double-blind， placebo-controlled， dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis&Rheumatismvol，2005，52(3)：916–923.
[21] Michael A.Becker， M.D.， H. Ralph Schumacher， et al.Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout [J].N Engl J Med， 2005， 353(23)：916-923.
[22] Ralph H，Schumacher JR，Michael A，et al. Effects of febuxostat versus allopurinol and placebo in educing serum urate in subjects with hypemricem is and gout a 28-week，phaseⅢ randomized double-blind， parallel-group trial[J].Arthrifis Rheum，2008，59(11)：1540-1548.
[23] Full Prescribing Information of Uloric[EB/OL].htqx//www.uloric.com/.
[24] Tim L，Pascal Richette.Internation Position Paper on Febuxostat[J].Clinical Rheumatology，2010(29)：835-840.
(收稿日期：2013-04-23), http://www.100md.com(刘慧)
[20] Michael A. Becker，H. Ralph Schumacher，Jr. Robert L. Wortmann，et al.Febuxostat， a novel nonpurine selective inhibitor of xanthine oxidase a twenty-eight-day， multicenter， phase II， randomized， double-blind， placebo-controlled， dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis&Rheumatismvol，2005，52(3)：916–923.
[21] Michael A.Becker， M.D.， H. Ralph Schumacher， et al.Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout [J].N Engl J Med， 2005， 353(23)：916-923.
[22] Ralph H，Schumacher JR，Michael A，et al. Effects of febuxostat versus allopurinol and placebo in educing serum urate in subjects with hypemricem is and gout a 28-week，phaseⅢ randomized double-blind， parallel-group trial[J].Arthrifis Rheum，2008，59(11)：1540-1548.
[23] Full Prescribing Information of Uloric[EB/OL].htqx//www.uloric.com/.
[24] Tim L，Pascal Richette.Internation Position Paper on Febuxostat[J].Clinical Rheumatology，2010(29)：835-840.
(收稿日期：2013-04-23), http://www.100md.com(刘慧)